{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:37:26Z","timestamp":1777581446947,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyze the efficacy of liposomal ozonated oil (Ozonest\u00ae) treatment, in patients with blepharitis or blepharoconjunctivitis, in improving the signs and symptoms of the pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Exploratory, open-label, prospective, single-arm, pre-post comparative pilot study in usual clinical practice, in 20 patients with blepharitis\/blepharoconjunctivitis, receiving treatment with liposomal ozonated oil, one drop in each eye, 4 times a day, for 28 days. Main purpose was to assess whether there was a clinically improvement in the blepharitis specific BLISS questionnaire score. Changes in the 12-item OSDI, in eyelid signs of blepharitis assessed by the physicians were also evaluated among other tests, and there was also a subjective evaluation of the treatment by patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The BLISS score significantly improved from 16.4 before treatment to 11.8 after treatment (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.05). The OSDI score was also significantly improved from 27.5 before treatment to 20.5 after treatment (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.05). All tests conducted before and after treatment showed significant improvement (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.05), except for NIBUT. The treatment received a score of 7 out of 10 by the patients. There were no adverse events in any patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Liposomal ozonated oil treatment showed good efficacy in improving the signs and symptoms of blepharitis\/blepharoconjunctivitis, satisfaction of patients, and good safety and tolerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721231207116","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T19:00:53Z","timestamp":1697482853000},"page":"678-682","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Liposomal ozonated oil effectiveness in the signs and symptoms of blepharitis in usual clinical practice"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2010-1701","authenticated-orcid":false,"given":"Jose Manuel","family":"Ben\u00edtez-Del-Castillo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hospital Cl\u00ednico San Carlos de Madrid, Madrid, Spain"},{"name":"Universidad Complutense de Madrid, Instituto de Investigaciones Oftalmol\u00f3gicas Ram\u00f3n Castroviejo, Madrid, Spain"},{"name":"Ocular Surface and Dry Eye Unit, Cl\u00ednica Rementer\u00eda, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.10.019"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/pir.25-9-312"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3467620"},{"key":"e_1_3_3_5_2","article-title":"Oral antibiotics for chronic blepharitis","volume":"6","author":"Onghanseng N","year":"2021","unstructured":"Onghanseng N, Ng SM, Halim MS, et al. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev 2021; 6: CD013697.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_6_2","volume-title":"StatPearls","author":"Eberhardt M","unstructured":"Eberhardt M, Rammohan G. Blepharitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing, January 23, 2023."},{"key":"e_1_3_3_7_2","first-page":"728","article-title":"Combined intense pulsed light and low-level light therapy for the treatment of refractory Meibomian gland dysfunction","author":"Meduri A","unstructured":"Meduri A, Oliverio GW, Tedesco G, et al. Combined intense pulsed light and low-level light therapy for the treatment of refractory Meibomian gland dysfunction. Eur J Ophthalmol 2023; 33: 728\u2013734. doi:https:\/\/doi.org\/10.1177\/11206721221127206","journal-title":"Eur J Ophthalmol"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0085"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25020334"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.4236\/jbise.2019.127026"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/157489109788490271"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000488846"},{"key":"e_1_3_3_13_2","unstructured":"Ozodrop [Internet]. FB Vision https:\/\/www.fb-vision.it\/prodotto\/ozodrop\/ (cited 2021 Mar 6)."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4081\/ozone.2017.6743"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.4081\/ozone.2019.8377"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107848"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01503-4"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.jcrs.0000000000000672"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-0839-5"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S360929"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10060968"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.4081\/ozone.2017.6743"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721231207116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721231207116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721231207116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:45:38Z","timestamp":1777405538000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721231207116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1177\/11206721231207116"],"URL":"https:\/\/doi.org\/10.1177\/11206721231207116","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]}}}